1132 related articles for article (PubMed ID: 9930550)
21. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
22. The chronic myeloproliferative disorders: an historical perspective.
Steensma DP
Curr Hematol Rep; 2003 May; 2(3):221-30. PubMed ID: 12901343
[TBL] [Abstract][Full Text] [Related]
23. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
Mesa RA; Elliott MA; Tefferi A
Blood Rev; 2000 Sep; 14(3):121-9. PubMed ID: 10986148
[TBL] [Abstract][Full Text] [Related]
24. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
25. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
Tefferi A; Thiele J; Vardiman JW
Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
[TBL] [Abstract][Full Text] [Related]
26. [Chronic myeloproliferative disorders. The new WHO classification].
Thiele J; Kvasnicka HM
Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643
[TBL] [Abstract][Full Text] [Related]
27. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
29. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
[TBL] [Abstract][Full Text] [Related]
30. Stem cell origin of human myeloid blood cell neoplasms.
Fialkow PJ
Verh Dtsch Ges Pathol; 1990; 74():43-7. PubMed ID: 1708632
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
Thiele J; Kvasnicka HM; Vardiman J
Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
[TBL] [Abstract][Full Text] [Related]
32. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
33. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
34. Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Nakata Y
Hiroshima J Med Sci; 1993 Jun; 42(2):67-71. PubMed ID: 8253600
[TBL] [Abstract][Full Text] [Related]
35. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD).
Bartl R; Frisch B; Wilmanns W
Eur J Haematol; 1993 Jan; 50(1):41-52. PubMed ID: 8436214
[TBL] [Abstract][Full Text] [Related]
36. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
37. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():193-203. PubMed ID: 12430925
[TBL] [Abstract][Full Text] [Related]
38. Low incidence of familial occurrence of thrombocythaemia and/or thrombocytosis.
Randi ML; Fabris F; Visentin I; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(5):695-9. PubMed ID: 2465250
[TBL] [Abstract][Full Text] [Related]
39. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
Kvasnicka HM; Thiele J
Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
[TBL] [Abstract][Full Text] [Related]
40. An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos.
Ruiz-Argüelles GJ; López-Martínez B; Lobato-Mendizábal E; Ruiz-Delgado GJ
Int J Hematol; 2002 Jun; 75(5):499-502. PubMed ID: 12095150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
